BioSpace News Archive

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, provided an update regarding the impact of the COVID-19 pandemic on its overall business continuity, including clinical trials, supply chain, and discovery research.

Phase 1 Study Combining Tumor Infiltrating Lymphocytes (TIL) and Nivolumab in Non-Small Cell Lung Cancer Funded in Part by Iovance and Stand Up To Cancer

As per the report compiled by Persistence Market Research (PMR), the global automated liquid handling system market is likely to witness significant growth. The market is projected to garner 6.4% CAGR throughout the forecast period. Towards the end of 2026, the global automated liquid handling system market is projected to bring in US$ 1,438.7 million in revenue.

Zomedica Pharmaceuticals Corp. announced that, on April 7, 2020, the Company filed with the United States Securities and Exchange Commission a Current Report on Form 8-K providing an update on the effect of the novel coronavirus pandemic on its operations.

Amyris Inc. today announced the full market launch and sales of its Pipette branded hand sanitizer

RNAi Represents One of the Most Promising and Rapidly Advancing Frontiers in Biology and Drug Development Today with Potential to Transform Lives of Patients – – Blackstone Provides a Customized Investment at Scale to Enable Alnylam to Achieve Self-sustainable Financial Profile Without Need for Future Equity Financing –

HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced the closing of its previously announced underwritten public offering (the “Offering”) for total gross proceeds to the Company of approximately C$46 million.

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices, solutions and a digital health platform to aid in the diagnosis of respiratory sleep disorders, today provided an update on actions the Company is taking in response to the COVID-19 pandemic.

WAT Medical Enterprise Ltd. conducted an investigation on solutions to cyber sickness (a form of nausea-induced vomiting). WAT Medical team has been studying has achieved positive results with the use of EmeTerm.

Eurofins Discovery’s mission is to support Pharmaceutical and Biotech companies in their efforts to accelerate drug discovery research and development.